Global deep brain stimulators market is expected to grow at a CAGR of around 7% during the forecast period. Deep Brain Stimulation is a device used for the treatment of neurological disorders such as Parkinson’s, Alzheimer’s and other psychiatric disorders such as dystonia, epilepsy, essential tremor, obsessive-compulsive disorder. It involves device implantation, referred to a neurostimulator. The neurostimulator works by transmitting electrical impulses through implanted electrodes, to particular targets in the brain. This, in turn, enables the treatment of neurological conditions. It is a minimally invasive procedure. The DBS consist of mainly three components, such as the lead, the extension and the implanted pulse generator (IPG). These components are surgically implanted inside the body.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/deep-brain-stimulators-market
The crucial factors that are driving the demand for deep brain stimulation include the growing prevalence of neurological and psychiatric disorders. According to the Parkinson’s Foundation, every year, nearly 60,000 Americans are diagnosed with Parkinson’s disease. Moreover, over 10 million people are living with Parkinson’s globally. The possibility of having Parkinson’s among men is 1.5 times more compared to women. The incidences of Parkinson’s disease rise with the age, however, an estimated 4% of people suffering from the disease are diagnosed earlier age 50. DBS enables for the treatment of Parkinson’s symptoms such as trouble walking, stiffness and tremors. It can also be used for the treatment of side effects associated with Parkinson’s medicines. Hence, such a rise in the prevalence of Parkinson’s disease is primarily boosting the demand for deep brain stimulators devices.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/deep-brain-stimulators-market
Few players operating in the global deep brain stimulators market include Medtronic PLC, Abbott Laboratories Inc., Boston Scientific Corp., LivaNova PLC, Cochlear, Ltd., Sonova Holding AG, Nevro Corp., ElectroCore LLC, and BioElectronics Corp. The market players adopt various strategies to expand their market share. For instance, in 2018, Abbott Laboratories, Inc. has declared FDA approval related to the over-the-air software upgrade for Infinity DBS systems. This enables to offer magnetic-resonance (MR)-conditional labeling and advanced features that will strengthen Infinity DBS system.
Market Segmentation
By Product
- Single Channel
- Dual Channel
By Applications
- Parkinson’s Disease
- Depression
- Others
By End-User
- Hospitals and Clinics
- Research Institutes and Other
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
Rest of the World
Company Profiles
- Abbott Laboratories (St. Jude Medical)
- Beijing PINS Medical Co. Ltd.
- Boston Scientific Corp.
- Fisher Wallace
- Functional Neuromodulation Ltd.
- Medtronic PLC
- NeuroPace Inc.
- Renishaw PLC
- Enteromedics
- Cyberonics
- Neurosigma
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
